US FDA approved on December 21, 2021, Holy Stone Healthcare’s application for compassionate use of CA102N in phase I clinical trials.
Holy Stone Healthcare submitted an application to the US FDA for compassionate use of its new drug, CA102N, for the treatment of colorectal cancer, in phase I clinical trials.
Holy Stone Healthcare participated in the National Invention and Creation Awards with its patented invention “Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease”.
Holy Stone Healthcare Co., Ltd. has received marketing authorization for NexoBrid® for the Treatment of Severe Thermal Burns
Holy Stone Healthcare’s new drug, ND108E, for the treatment of neurodegenerative diseases, has been granted a Patent by the Taiwan Intellectual Property Office (TIPO)
Holy Stone Healthcare’s new drug, CA102N, for the treatment of colorectal cancer, has been granted a European Patent by the European Patent Office (EPO)
The study result of “Anticancer activity of CA102N in breast cancer cells in vitro and in vivo” was presented during the Annual Meeting of the American Association of Cancer Research
Holy Stone Healthcare and Gongwin Biopharm will cooperate in conducting IBD98-M Phase II Clinical Trial in China. Both parties will invest funds and manpower in this case. The remarkable experience of Gongwin Biopharm in conducting clinical trials in China, as well as its vast networks will benefit the planning and conducting of future clinical trials. In addition, both parties will cultivate the licensing opportunities in the Chinese market, in order to create a new blueprint and share the profit.
Holy Stone Healthcare’s patent “Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease” received silver award at 2020 National Invention and Creation Awards
The study result of “CA102N suppresses the growth of mouse colon cancer by inhibition of PI3K pathway and immune modulation” will be presented during the Annual Meeting of American Association of Cancer Research
Holy Stone Healthcare Co., Ltd. attended 2019 BIO International Convention in Philadelphia, USA on June 3-6.
Holy Stone Healthcare participates in the Atlanta 2019 AACR Annual Meeting (2019/3/29-4/3) poster presentation.